Reply to Volkman et al. Comment on “Fust et al. The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan. Vaccines 2024, 12, 434”

Authors

Institutions

Publication Details

Journal
Vaccines
Published
2024-10-17
DOI
https://doi.org/10.3390/vaccines12101175
Primary Topic
SARS-CoV-2 and COVID-19 Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Reply to Volkman et al. Comment on “Fust et al. The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan. Vaccines 2024, 12, 434”

Nicolas Van de Velde, Yuriko Hagiwara, Keya Joshi, Ekkehard Beck et al.
Vaccines
SARS-CoV-2 and COVID-19 Research
article

Reply to Volkman et al. Comment on “Fust et al. The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan. Vaccines 2024, 12, 434”

Nicolas Van de Velde, Yuriko Hagiwara, Keya Joshi, Ekkehard Beck, Ataru Igarashi, Michele Kohli
article en

Abstract

No abstract available for this paper.
VaccinesVol. 12(10)
Moderna Therapeutics (United States) (US), The University of Tokyo (JP)
Pfizer, Moderna
Zero hunger
Openalex Percentile: Top 77%
SARS-CoV-2 and COVID-19 Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.